Metraipolis › archive › dc_28f22e61eceb

Evaluating Chemicals for Thyroid Disruption: Opportunities and Challenges with in Vitro Testing and Adverse Outcome Pathway Approaches — Europe PMC PMID:31487205

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/31487205
DOI
10.1289/ehp5297
License (as archived)
CC0-1.0
Archived
2026-11-10T17:03:57.413Z
SHA-256 of the archived text
6e5496af96a6b146dc78cb0c9c01cc0bcd268554ac2f88d21033bfed4ac29b09
Stable URL of this page
https://metraipolis.com/documento/dc_28f22e61eceb

How to cite

Evaluating Chemicals for Thyroid Disruption: Opportunities and Challenges with in Vitro Testing and Adverse Outcome Pathway Approaches — Europe PMC PMID:31487205 — Europe PMC (en), https://europepmc.org/article/MED/31487205 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_28f22e61eceb (Metraipolis archive dc_28f22e61eceb, sha256 6e5496af96a6b146dc78cb0c9c01cc0bcd268554ac2f88d21033bfed4ac29b09)
BibTeX
@misc{dc28f22e61eceb,
  title = {Evaluating Chemicals for Thyroid Disruption: Opportunities and Challenges with in Vitro Testing and Adverse Outcome Pathway Approaches — Europe PMC PMID:31487205},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/31487205},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_28f22e61eceb; sha256 6e5496af96a6b146dc78cb0c9c01cc0bcd268554ac2f88d21033bfed4ac29b09},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/31487205. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: Extensive clinical and experimental research documents the potential for chemical disruption of thyroid hormone (TH) signaling through multiple molecular targets. Perturbation of TH signaling can lead to abnormal brain development, cognitive impairments, and other adverse outcomes in humans and wildlife. To increase chemical safety screening efficiency and reduce vertebrate animal testing, in vitro assays that identify chemical interactions with molecular targets of the thyroid system have been developed and implemented. Objectives: We present an adverse outcome pathway (AOP) network to link data derived from in vitro assays that measure chemical interactions with thyroid molecular targets to downstream events and adverse outcomes traditionally derived from in vivo testing. We examine the role of new in vitro technologies, in the context of the AOP network, in facilitating consideration of several important regulatory and biological challenges in characterizing chemicals that exert effects through a thyroid mechanism. Discussion: There is a substantial body of knowledge describing chemical effects on molecular and physiological regulation of TH signaling and associated adverse outcomes. Until recently, few alternative nonanimal assays were available to interrogate chemical effects on TH signaling. With the development of these new tools, screening large libraries of chemicals for interactions with molecular targets of the thyroid is now possible. Measuring early chemical interactions with targets in the thyroid pathway provides a means of linking adverse outcomes, which may be influenced by many biological processes, to a thyroid mechanism. However, the use of in vitro assays beyond chemical screening is complicated by continuing limits in our knowledge of TH signaling in important life stages and tissues, such as during fetal brain development. Nonetheless, the thyroid AOP network provides an ideal tool for defining causal linkages of a chemical exerting thyroid-dependent effects and identifying research needs to quantify these effects in support of regulatory decision making. https://doi.org/10.1289/EHP5297.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: Environmental health perspectives, 2019 (prima pubblicazione 2019-09-05).
Identificativi: PMID 31487205 · PMCID PMC6791490 · DOI 10.1289/ehp5297.
Descrittori MeSH principali: Adverse Outcome Pathways.
Pagina: https://europepmc.org/article/MED/31487205 — https://doi.org/10.1289/ehp5297. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-10T16:52:07.354Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.